News

European Medical Journal2d

Long-Term Effect of Selexipag in Systemic Sclerosis-Associated Digital Ulcers: A Case Control, Multicentre, Observational Study

Digital ulcers (DU) affect approximately 50% of patients with systemic sclerosis (SSc), causing significant pain ...
pharmaphorum5d

Data at EULAR back Biogen, UCB's first-in-class lupus drug

Hopes rise for a new treatment option for people living with lupus, after UCB and Biogen reveal phase 3 data with their anti-CD40L antibody DZP.